Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
2023-508743-43-00Phase 4Completed
- Sponsor
- National Institute of Cardiology
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amiodarone, bisoprolol, metoprolol and sotalol in Atrial fibrillation (AFib) and hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by National Institute of Cardiology. Primary endpoint: Composite of death, stroke/TIA, or unscheduled medical intervention. Started Mar 2024; status: completed.
02
Drugs
amiodaronebisoprololmetoprololsotalol
03
Conditions
Atrial fibrillation (AFib)hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2023-508743-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508743-43-00.